New Protocol Design Approaches Will Improve Clinical Trial Performance and Efficiency, According to Tufts Center for the Study of Drug Development
April 09, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Apr 9, 2013) - Growing protocol complexity -- responsible for longer clinical study times, greater difficulty in recruiting volunteers, and rising drug development costs...
Investigative Site Landscape Remains Highly Fragmented as the Number of Active Investigators Worldwide Reaches an All-Time High, According to the Tufts Center for the Study of Drug Development
March 12, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Mar 12, 2013) - More than half of all clinical trials worldwide that are regulated by the U.S. Food and Drug Administration (FDA) were conducted by independent,...
Companion Diagnostics, Key to Development of Personalized Medicines, Face Hurdles, According to Tufts Center for the Study of Drug Development
January 24, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 24, 2013) - Companion diagnostics, which are central to the creation of personalized medicines, have captured the interest of many drug companies, but face a number of...
New Research From Tufts Center for the Study of Drug Development Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices
January 15, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 15, 2013) - While nine out of 10 clinical trials worldwide meet their patient enrollment goals, reaching those targets typically means that drug developers need to...
Drug Developers Need to More Fully Identify and Address Root Causes of R&D Inefficiency, According to Tufts Center for the Study of Drug Development
January 08, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 8, 2013) - While patent expirations on many top selling medicines are spurring the research-based drug industry to embrace new development paradigms to replenish...
Extraneous Data Collected in Clinical Trials Cost Drug Developers $4 Billion to $6 Billion Annually, According to Tufts Center for the Study of Drug Development
November 06, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Nov 6, 2012) - One out of every five procedures performed during later stage clinical trials collects extraneous data and costs drug developers more than $1 million per...
Contract Support and Technical Service Providers Expected to Play a Growing Role in Drug Development, According to Tufts Center for the Study of Drug Development
October 17, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Oct 17, 2012) - Drug sponsors and their contract service providers are using more sophisticated, integrated, and coordinated relationship structures to deliver greater...
Oncology Drugs Get Faster Approvals Than Non-Oncology Drugs in U.S., but the Opposite Is True in the EU, According to Tufts Center for the Study of Drug Development
September 05, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Sep 5, 2012) - Approval times for new oncology drugs in the United States during the last decade were shorter than approval times for non-oncology products, while the...
Drug Companies Are Teaming With Academic Medical Centers to Create New Medicines, According to Tufts Center for the Study of Drug Development
August 07, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Aug 7, 2012) - Drug developers are forging new ways to work with academic medical centers to create the next generation of breakthrough medicines, which is changing the...
U.S. Cancer Patients Get Faster Access to More Oncology Drugs Than European Patients, According to Tufts Center for the Study of Drug Development
July 10, 2012 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jul 10, 2012) - Cancer patients in the United States get faster access to more oncology drugs to treat their disease than patients in Europe, according to a newly...